메뉴 건너뛰기




Volumn 12, Issue 9, 2006, Pages 714-725

Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting

Author keywords

Anemia; Nondialysis chronic kidney disease; Patterns of nephrology care; Resource requirement; Routine ESP administration

Indexed keywords

ERYTHROPOIETIN; PROTEIN;

EID: 33847337570     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.9.714     Document Type: Article
Times cited : (14)

References (47)
  • 1
    • 8844233416 scopus 로고    scopus 로고
    • Chronic kidney disease: Prevention and treatment of common complications
    • Snively CS, Gutierrez C. Chronic kidney disease: prevention and treatment of common complications. Am Fam Physician. 2004;70(10):1921-28.
    • (2004) Am Fam Physician , vol.70 , Issue.10 , pp. 1921-1928
    • Snively, C.S.1    Gutierrez, C.2
  • 2
    • 4644252248 scopus 로고    scopus 로고
    • State-specific trends in chronic kidney failure - United States, 1990-2001
    • Centers for Disease Control and Prevention
    • Centers for Disease Control and Prevention. State-specific trends in chronic kidney failure - United States, 1990-2001. MMWR Morb Mortal Wkly Rep. 2004;53(39):918-20.
    • (2004) MMWR Morb Mortal Wkly Rep , vol.53 , Issue.39 , pp. 918-920
  • 3
    • 85039232111 scopus 로고    scopus 로고
    • Office of Disease Prevention and Health Promotion (ODPHP). Chronic kidney disease: A silent threat
    • U.S. Department of Health and Human Services, 18(4):1-6. Available at:, Accessed June 9
    • U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion (ODPHP). Chronic kidney disease: a silent threat. Prevention Report 2004;18(4):1-6. Available at: http://odphp.osophs. dhhs.gov/pubs/prevrpt/04Volume18/Iss4Vol18.pdf. Accessed June 9, 2006.
    • (2006) Prevention Report 2004
  • 4
    • 4444252535 scopus 로고    scopus 로고
    • Clinical practice guidelines for chronic kidney disease in adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors
    • Johnson CA, Levey AS, Coresh J, Levin A, Lau J, Eknoyan G. Clinical practice guidelines for chronic kidney disease in adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors. Am Fam Physician. 2004;70(5):869-76.
    • (2004) Am Fam Physician , vol.70 , Issue.5 , pp. 869-876
    • Johnson, C.A.1    Levey, A.S.2    Coresh, J.3    Levin, A.4    Lau, J.5    Eknoyan, G.6
  • 5
    • 1642413198 scopus 로고    scopus 로고
    • Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization
    • Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659-63.
    • (2004) Arch Intern Med , vol.164 , pp. 659-663
    • Keith, D.S.1    Nichols, G.A.2    Gullion, C.M.3    Brown, J.B.4    Smith, D.H.5
  • 6
    • 0034927743 scopus 로고    scopus 로고
    • Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the third National Health and Nutrition Examination Survey (1988-1994)
    • Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the third National Health and Nutrition Examination Survey (1988-1994). Arc h Intern Med. 2001;161(9):1207-16.
    • (2001) Arc h Intern Med , vol.161 , Issue.9 , pp. 1207-1216
    • Coresh, J.1    Wei, G.L.2    McQuillan, G.3
  • 8
    • 1642502319 scopus 로고    scopus 로고
    • National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
    • Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137-47.
    • (2003) Ann Intern Med , vol.139 , Issue.2 , pp. 137-147
    • Levey, A.S.1    Coresh, J.2    Balk, E.3
  • 9
    • 0036176161 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
    • National Kidney Foundation
    • National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
    • (2002) Am J Kidney Dis , vol.39 , Issue.2 SUPPL. 1
  • 10
    • 33646345152 scopus 로고    scopus 로고
    • K/DOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 suppl 3):S11-S145.
    • K/DOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 suppl 3):S11-S145.
  • 11
    • 5444255241 scopus 로고    scopus 로고
    • The prevalence of anemia in patients with chronic kidney disease
    • McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20(9):1501-10.
    • (2004) Curr Med Res Opin , vol.20 , Issue.9 , pp. 1501-1510
    • McClellan, W.1    Aronoff, S.L.2    Bolton, W.K.3
  • 12
    • 1542342375 scopus 로고    scopus 로고
    • the PAERI Study Group. The prevalence of anemia in patients with chronic kidney disease: Final results from the PAERI study
    • McClellan W, Tran LL, the PAERI Study Group. The prevalence of anemia in patients with chronic kidney disease: final results from the PAERI study. J Am Soc Nephrol. 2002;13:461A.
    • (2002) J Am Soc Nephrol , vol.13
    • McClellan, W.1    Tran, L.L.2
  • 13
    • 20144386857 scopus 로고    scopus 로고
    • Quality of life in chronic kidney disease (CKD): A cross-sectional analysis in the renal research institute-CKD study
    • Perlman R, Finkelstein F, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the renal research institute-CKD study. Am J Kidney Dis. 2005;45:658-66.
    • (2005) Am J Kidney Dis , vol.45 , pp. 658-666
    • Perlman, R.1    Finkelstein, F.2    Liu, L.3
  • 14
    • 0028918368 scopus 로고
    • Cardiac function and hematocrit level
    • Harnett JD, Kent GM, Foley RN, et al. Cardiac function and hematocrit level. Am J Kidney Dis. 1995;25(suppl 1):S3-S7.
    • (1995) Am J Kidney Dis , vol.25 , Issue.SUPPL. 1
    • Harnett, J.D.1    Kent, G.M.2    Foley, R.N.3
  • 15
    • 0029959465 scopus 로고    scopus 로고
    • The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
    • Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53-61.
    • (1996) Am J Kidney Dis , vol.28 , pp. 53-61
    • Foley, R.N.1    Parfrey, P.S.2    Harnett, J.D.3
  • 16
    • 0034256021 scopus 로고    scopus 로고
    • Hematocrit levels and associated Medicare expenditures
    • Collins AJ, Li S, Ebben J, et al. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis. 2000;36:282-93.
    • (2000) Am J Kidney Dis , vol.36 , pp. 282-293
    • Collins, A.J.1    Li, S.2    Ebben, J.3
  • 17
    • 31344445271 scopus 로고    scopus 로고
    • Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) Study
    • Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2006;151(2):492-500.
    • (2006) Am Heart J , vol.151 , Issue.2 , pp. 492-500
    • Astor, B.C.1    Coresh, J.2    Heiss, G.3    Pettitt, D.4    Sarnak, M.J.5
  • 18
    • 31544469806 scopus 로고    scopus 로고
    • Association of anemia with outcomes in men with moderate and severe chronic kidney disease
    • Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006;69:560-64.
    • (2006) Kidney Int , vol.69 , pp. 560-564
    • Kovesdy, C.P.1    Trivedi, B.K.2    Kalantar-Zadeh, K.3
  • 19
    • 0028945387 scopus 로고
    • Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients
    • Revicki D, Brown R, Feeny D, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25:548-54.
    • (1995) Am J Kidney Dis , vol.25 , pp. 548-554
    • Revicki, D.1    Brown, R.2    Feeny, D.3
  • 20
    • 9144264827 scopus 로고    scopus 로고
    • Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
    • Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19(1):121-32.
    • (2004) Nephrol Dial Transplant , vol.19 , Issue.1 , pp. 121-132
    • Locatelli, F.1    Pisoni, R.L.2    Combe, C.3
  • 22
    • 3042772186 scopus 로고    scopus 로고
    • Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
    • Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44(1):94-111.
    • (2004) Am J Kidney Dis , vol.44 , Issue.1 , pp. 94-111
    • Pisoni, R.L.1    Bragg-Gresham, J.L.2    Young, E.W.3
  • 23
    • 85039203427 scopus 로고    scopus 로고
    • U.S. Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: U.S. Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005:88-89.
    • U.S. Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: U.S. Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005:88-89.
  • 25
    • 85039218842 scopus 로고    scopus 로고
    • U.S. Food and Drug Administration. List of orphan products designations and approvals (through December 31, 1999). Available at: http://www.fda.gov/ ohrms/dockets/dailys/00/mar00/030100/lst0094.pdf. Accessed November 10, 2006.
    • U.S. Food and Drug Administration. List of orphan products designations and approvals (through December 31, 1999). Available at: http://www.fda.gov/ ohrms/dockets/dailys/00/mar00/030100/lst0094.pdf. Accessed November 10, 2006.
  • 26
    • 0003775081 scopus 로고
    • Committee for the Study of the Medicare End-Stage Renal Disease Program, Division of Health Care Services, Institute of Medicine
    • Rettig RA, Levinsky NG, eds, Washington DC: National Academy Press, Available at:, Accessed November 10
    • Rettig RA, Levinsky NG, eds. Committee for the Study of the Medicare End-Stage Renal Disease Program, Division of Health Care Services, Institute of Medicine. Kidney Failure and the Federal Government. Washington DC: National Academy Press, 1991. Available at: http://fermat.nap.edu/books/ 0309044324/html. Accessed November 10, 2006.
    • (1991) Kidney Failure and the Federal Government
  • 27
    • 85039238240 scopus 로고    scopus 로고
    • The Biopharmaceuticals. FDA-approved biopharmaceutical drugs and vaccines [online]. Available at: http://www.accessexcellence.org/RC/AB/BA/ The_Biopharmaceuticals.html. Accessed November 10, 2006.
    • The Biopharmaceuticals. FDA-approved biopharmaceutical drugs and vaccines [online]. Available at: http://www.accessexcellence.org/RC/AB/BA/ The_Biopharmaceuticals.html. Accessed November 10, 2006.
  • 28
    • 85039234915 scopus 로고    scopus 로고
    • Columbia, co-transformation, commercialization & controversy: the Axel patent litigation. Harvard J Law Technol [online]. 2004;17(2):538-618. Available at: http://jolt.law.harvard.edu/articles/pdf/v17/ 17HarvJLTech583.pdf. Accessed November 10, 2006.
    • Columbia, co-transformation, commercialization & controversy: the Axel patent litigation. Harvard J Law Technol [online]. 2004;17(2):538-618. Available at: http://jolt.law.harvard.edu/articles/pdf/v17/ 17HarvJLTech583.pdf. Accessed November 10, 2006.
  • 29
    • 72449133295 scopus 로고    scopus 로고
    • U.S. Food and Drug Administration, online, Available at:, Accessed November 10
    • U.S. Food and Drug Administration. FDA approved drug products [online]. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed November 10, 2006.
    • (2006) FDA approved drug products
  • 30
    • 18744363354 scopus 로고    scopus 로고
    • Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease
    • Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005;63(5):327-34.
    • (2005) Clin Nephrol , vol.63 , Issue.5 , pp. 327-334
    • Ling, B.1    Walczyk, M.2    Agarwal, A.3    Carroll, W.4    Liu, W.5    Brenner, R.6
  • 31
    • 34548554731 scopus 로고    scopus 로고
    • Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: A multicentre, open-label, Australian study
    • Disney A, de Jersey P, Kirkland G, et al. Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: a multicentre, open-label, Australian study. Nephrology. 2006;260(6):577-85.
    • (2006) Nephrology , vol.260 , Issue.6 , pp. 577-585
    • Disney, A.1    de Jersey, P.2    Kirkland, G.3
  • 32
    • 85039198339 scopus 로고    scopus 로고
    • An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis
    • In press
    • Agarwal AK, Silver MR, Reed JE, et al. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med. In press.
    • J Intern Med
    • Agarwal, A.K.1    Silver, M.R.2    Reed, J.E.3
  • 33
    • 23144460027 scopus 로고    scopus 로고
    • PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study
    • Provenzano R, Bhaduri S, Singh AK; PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol. 2005;64(2):113-23.
    • (2005) Clin Nephrol , vol.64 , Issue.2 , pp. 113-123
    • Provenzano, R.1    Bhaduri, S.2    Singh, A.K.3
  • 34
    • 0036760032 scopus 로고    scopus 로고
    • Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia
    • Piccoli A, Malagoli A, Komninos G, et al. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia. J Nephrol. 2002;15:565-74.
    • (2002) J Nephrol , vol.15 , pp. 565-574
    • Piccoli, A.1    Malagoli, A.2    Komninos, G.3
  • 35
    • 0037255238 scopus 로고    scopus 로고
    • Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease
    • Suranyi MG, Lindberg JS, Navarro J, et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol. 2003;23:106-11.
    • (2003) Am J Nephrol , vol.23 , pp. 106-111
    • Suranyi, M.G.1    Lindberg, J.S.2    Navarro, J.3
  • 36
    • 4644357756 scopus 로고    scopus 로고
    • Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration
    • Toto RD, Pichette V, Navarro J, et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol. 2004;24:453-60.
    • (2004) Am J Nephrol , vol.24 , pp. 453-460
    • Toto, R.D.1    Pichette, V.2    Navarro, J.3
  • 37
    • 14544272966 scopus 로고    scopus 로고
    • Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia
    • Available at:, Accessed October 30, 2006
    • Crémieux PY, Fastenau JM, Kosicki G, Piech CT, Fendrick AM. Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia. J Manag Care Pharm. 2004;10(6):531-37. Available at: http://www.amcp.org/data/jmcp/Formulary%20Management-531-537.pdf. Accessed October 30, 2006.
    • (2004) J Manag Care Pharm , vol.10 , Issue.6 , pp. 531-537
    • Crémieux, P.Y.1    Fastenau, J.M.2    Kosicki, G.3    Piech, C.T.4    Fendrick, A.M.5
  • 38
    • 0036724388 scopus 로고    scopus 로고
    • Health care resource utilization and the impact of anemia management in patients with chronic kidney disease
    • London R, Solis A, Goldberg GA, Wade S, Ryu S. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis. 2002;40:539-48.
    • (2002) Am J Kidney Dis , vol.40 , pp. 539-548
    • London, R.1    Solis, A.2    Goldberg, G.A.3    Wade, S.4    Ryu, S.5
  • 39
    • 0037466966 scopus 로고    scopus 로고
    • Alcohol consumption and expenditures for underage drinking and adult excessive drinking
    • Foster SE, Vaughan RD, Foster WH, Califano JA Jr. Alcohol consumption and expenditures for underage drinking and adult excessive drinking. JAMA. 2003;289:989-95.
    • (2003) JAMA , vol.289 , pp. 989-995
    • Foster, S.E.1    Vaughan, R.D.2    Foster, W.H.3    Califano Jr., J.A.4
  • 40
    • 0017360990 scopus 로고
    • The measurement of observer agreement for categorical data
    • Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-74.
    • (1977) Biometrics , vol.33 , pp. 159-174
    • Landis, J.R.1    Koch, G.G.2
  • 41
    • 48249153186 scopus 로고
    • Intraclass correlations: Uses in assessing rater reliability
    • Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychological Bulletin. 1979;86:420-28.
    • (1979) Psychological Bulletin , vol.86 , pp. 420-428
    • Shrout, P.E.1    Fleiss, J.L.2
  • 42
    • 0344874268 scopus 로고    scopus 로고
    • Impact of long-acting growth factors on practice dynamics and patient satisfaction
    • Beveridge RA, Rifkin RM, Moleski RJ, et al. Impact of long-acting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy. 2003;23(12 pt 2):101S-109S.
    • (2003) Pharmacotherapy , vol.23 , Issue.12 PART 2
    • Beveridge, R.A.1    Rifkin, R.M.2    Moleski, R.J.3
  • 43
    • 33748793448 scopus 로고    scopus 로고
    • Resource utilization and time commitment associated with correction of anaemia in cancer patients using epoetin alfa
    • Meehan KR, Tchekmedyian NS, Smith RE, Kallich J. Resource utilization and time commitment associated with correction of anaemia in cancer patients using epoetin alfa. Clin Drug Invest. 2006;26(10):593-601.
    • (2006) Clin Drug Invest , vol.26 , Issue.10 , pp. 593-601
    • Meehan, K.R.1    Tchekmedyian, N.S.2    Smith, R.E.3    Kallich, J.4
  • 44
    • 16244396713 scopus 로고    scopus 로고
    • Lessons learned in an urban CKD clinic
    • January
    • Crawford PW. Lessons learned in an urban CKD clinic. Nephrol News Issues. January 2005;43-48.
    • (2005) Nephrol News Issues , pp. 43-48
    • Crawford, P.W.1
  • 45
    • 23844476491 scopus 로고    scopus 로고
    • The role of the nurse practitioner in a CKD clinic
    • June
    • Calvin D, Roberts K. The role of the nurse practitioner in a CKD clinic. Nephrol News Issues. June 2005;26-29.
    • (2005) Nephrol News Issues , pp. 26-29
    • Calvin, D.1    Roberts, K.2
  • 46
    • 31544433971 scopus 로고    scopus 로고
    • Physician activities during time out of the examination room
    • Gilchrist V, McCord G, Schrop SL, et al. Physician activities during time out of the examination room. Ann Fam Med. 2005;3(6):494-99.
    • (2005) Ann Fam Med , vol.3 , Issue.6 , pp. 494-499
    • Gilchrist, V.1    McCord, G.2    Schrop, S.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.